SOGC Guidelines
-
Upload
agnes-montero-fenix -
Category
Documents
-
view
228 -
download
3
Transcript of SOGC Guidelines
![Page 1: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/1.jpg)
SOGC GuidelinesManagement of DUB
![Page 2: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/2.jpg)
Normal menstrual cycle
Interval: 28 + 7 days Flow: 4 + 2 days Average blood loss: 40 + 20 ml
![Page 3: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/3.jpg)
Hormonal regulation
![Page 4: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/4.jpg)
Abnormal uterine bleeding
Changes in frequency of menses, duration of flow or amount of blood loss
![Page 5: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/5.jpg)
Dysfunctional uterine bleeding
Diagnosis of exclusion No pelvic pathology or underlying medical
cause Heavy prolonged flow with or without
breakthrough bleeding With or without ovulation
![Page 6: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/6.jpg)
Menorrhagia (hypermenorrhea)
Heavy cyclical menstrual bleeding occurring over several cycles throughout reproductive years
Blood loss of more than 80 ml per cycle In excess of 60 ml per cycle results in iron
deficiency anemia and may affect quality of life
![Page 7: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/7.jpg)
Diagnostic approach to AUB
History and physical examination Assesment of endometrium
– Endometrial sampling– Dilatation and curettage– Transvaginal ultrasound– Saline sonohysterography
![Page 8: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/8.jpg)
History
Polyps or submucous myoma may be present in 25 to 50% of women with irregular bleeding
Distinguish between anovulatory and ovulatory DUB Anovulatory
– Extremes of age (adolescents and perimenopause)– Polycystic ovary syndrome
Identify risk factors
![Page 9: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/9.jpg)
Independent risk factors for endometrial hyperplasia and carcinoma in women with AUB
![Page 10: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/10.jpg)
Diagnosis
Abdomino pelvic exam necessary Pap smear and CBC TSH, prolactin, day 21 to 23 progesterone or
documentation of ovulation FSH or LH to verify menopausal status or to
check for PCO Coagulation profile especially for young
patients
![Page 11: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/11.jpg)
Ovulatory AUB
Heavy cyclical blood loss over several cycles without intermenstrual or postcoital bleeding
Dysmenorrhea with passage of clots Premenstrual symptoms suggest ovulatory
cycles
![Page 12: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/12.jpg)
Endometrial sampling
All women above age 40 or with higher risk for endometrial cancer
– Nulliparity with history of infertility– New onset heavy irregular bleeding– Obesity (>90 kg)– Polycystic ovaries– Family history of endometrial or colon cancer– Tamoxifen therapy
No improvement in bleeding after 3 month medical therapy
![Page 13: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/13.jpg)
Endometrial sampling
Office endometrial biopsy– Adequate samples in 87 to 97% and detects 67
to 96% of endometrial carcinomas– Hysteroscopically directed biopsies detects a
higher percentage compared with D and C alone
– Even if endometrium appears normal on hysteroscopy, the endometrium should be sampled since appearance not sufficient to exclude hyperplasia or carcinoma (EvL2a)
![Page 14: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/14.jpg)
Dilatation and curettage
No yield in 10 to 25% of women Morbidities: perforation in 0.6 to 1.3% and bleeding
in 0.4% Blind procedure with significant sampling errors Requires anesthesia with a risk of complications Reserved for situations where office biopsy or
hysteroscopy not feasible or available
![Page 15: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/15.jpg)
Transvaginal ultrasonography
Assess endometrial thickness Detect polyps and leiomyomata Sensitivity of 80% Specificity of 69%
![Page 16: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/16.jpg)
Transvaginal ultrasonography
Endometrial thickness of less than 5 mm can exclude endometrial disease and carcinoma with a sensitivity of 92% and 96% respectively
Not helpful if thickness is between 5 to 12 mm
No correlations established in premenopausal patients
![Page 17: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/17.jpg)
Saline infusion sonography
Introduction of 15 ml saline through catheter or pediatric feeding tube improves the diagnosis of endometrial masses during TVS
![Page 18: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/18.jpg)
Medical management
Age Desire to preserve fertility Coexisting medical conditions Patients’ preference Provide risks and contraindications Satisfaction depends on efficacy,
expectations, cost, inconvenience, side effects
![Page 19: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/19.jpg)
Medical managements
NSAIDs Antifibrinolytics Danazol Combined oral contraceptives Progestin intrauterine system GnRH agonists
![Page 20: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/20.jpg)
NSAIDs
Inhibit cyclo-oxygenase and reduce endometrial prostaglandin levels
Decrease menstrual blood loss by 20-25% Improve dysmenorrhea in up to 70% Initiated on first day of menses and
continued for five days or until cessation of menstruation (EvL1a)
![Page 21: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/21.jpg)
Antifibrinolytics
Tranexamic acid (derivative of amino acid lysine) provides reversible blockade of plasminogen
No effect on blood coagulation parameters nor dysmenorrhea
Side effects in 1/3 of women: nausea, leg cramps 500 mg every 6 hours for first 4 days of cycle
decreases bleeding in 40%
![Page 22: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/22.jpg)
Danazol
Synthetic steroid with mild androgenic properties inhibit steroidogenis in ovary and with profound effect in endometrial tissue
Reduces blood loss by up to 80% 100 to 200 mg daily for up to 6 months Amenorrhea in 20% and oligomenorrhea in 70% No side effects in 50%, with side effects in 20%
including weight gain of 2 to 6 lbs (60% of patients)
![Page 23: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/23.jpg)
Progestins
Ineffective in controlling heavy menstrual bleeding compared with NSAIDs or tranexamic acid
Useful in women with anovulatory cycles given 12 to 14 days each month
Medroxyprogesterone acetate produces amenorrhea in 80% but with irregular bleeding in 50%
![Page 24: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/24.jpg)
Combined oral contraceptives
Produces endometrial atrophy Intake of COC with 30g ethinyl estradiol
reduces blood loss of up to 43% from baseline
Provides contraception and relieves dysmenorrhea
![Page 25: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/25.jpg)
Progestin intrauterine system
Levonorgestrel IUD releases 20g/24 hours
![Page 26: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/26.jpg)
GnRH agonists
Produces reversible hypoestrogenic state and reduces uterine volume by 40 to 60%
Myomas and uterine volume expand to pretreatment levels within months of cessation of treatment
Effective but limited by side effects like hot flashes and reduction in bone density
![Page 27: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/27.jpg)
Surgical management
Dilatation and curettage Endometrial destruction Hysterectomy
![Page 28: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/28.jpg)
Dilatation and curettage
Temporary reduction in blood loss Useful in aiding diagnosis
![Page 29: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/29.jpg)
Endometrial ablation
85% satisfied patients in life table analysis of 6.5 years
10% will eventually have hysterectomy 10% will have repeat procedure after 5 years Women above 40 have better outcome Preoperative therapy improve ease of
surgery and short term amenorrhea rates
![Page 30: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/30.jpg)
Endometrial ablation
Hysterocopically guided Photo or electrocoagulation Rollerball or loop resection
![Page 31: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/31.jpg)
Endometrial ablation
Effective for chronic menorrhagia unresponsive to medication
Low complication rates, high satisfaction rates on long term follow up
Compares favorably with hysterectomy but need cost benefit analysis on long term if with repeat procedures necessary
![Page 32: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/32.jpg)
Global endometrial ablation
Uses heat or cold to destroy endometrium Requires less operator skills Efficacy and cost-effectiveness not
thoroughly evaluated Requires pre and post op visualization of
endometrium by hysteroscopy
![Page 33: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/33.jpg)
Hysterectomy
Risk of major surgery weighed against alternatives
Permanent solution for menorrhagia High levels of patient satisfaction in properly
selected patients For women who have completed
childbearing, reviewed other alternatives, conservative management has failed
![Page 34: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/34.jpg)
Take home points
1. Women with irregular menstrual bleeding should be investigated for endometrial polyps and/or submucous fibroids. (II-2 B)
![Page 35: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/35.jpg)
Take home points
2. Women presenting with menorrhagia should have a current cervical cytology and a complete blood count. Further investigations are individualized. It is useful to delineate if the bleeding results from ovulatory or anovulatory causes, both in terms of tailoring the investigations and in choosing a treatment. (III B)
![Page 36: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/36.jpg)
Take home points
3. Clinicians should perform endometrial sampling based on the methods available to them. An office endometrial biopsy should be obtained if possible in all women presenting with abnormal uterine bleeding over 40 years of age or weighing more than or equal to 90 kg. (II B)
![Page 37: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/37.jpg)
Take home points
3. Clinicians should perform endometrial sampling based on the methods available to them. An office endometrial biopsy should be obtained if possible in all women presenting with abnormal uterine bleeding over 40 years of age or weighing more than or equal to 90 kg. (II B)
![Page 38: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/38.jpg)
Take home points
4. Hysteroscopically-directed biopsy is indicated for women with persistent erratic menstrual bleeding, failed medical therapy or transvaginal saline sonography suggestive of focal intrauterine pathology such as polyps or myomas. Women with persistent symptoms but negative tests should be reevaluated. (II B)
![Page 39: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/39.jpg)
Take home points
5. Progestogens given in the luteal phase of the ovulatory menstrual cycles are not effective in reducing regular heavy menstrual bleeding . (I A)
![Page 40: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/40.jpg)
Take home points
6. While dilatation and curettage (D&C) may have a diagnostic role, it is not effective therapy for women with heavy menstrual bleeding. (II B)
![Page 41: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/41.jpg)
Take home points
7. The endometrium can be destroyed by several different techniques but reoperation rate at five years may be up to 40 percent with rollerball ablation. This should be reserved for the woman who has finished her childbearing and is aware of the risk of recurrent bleeding. (I A)
![Page 42: SOGC Guidelines](https://reader034.fdocuments.net/reader034/viewer/2022051613/55162f7c4979591d538b4e01/html5/thumbnails/42.jpg)
Thank you!